Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B patients without detectable lamivudine resistance

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 3, 2014, Pages 1730-1737

  Lee, Jeong Hoon ^a   Cho, Yuri ^a   Lee, Dong Hyeon ^a   Lee, Minjong ^a   Yoo, Jeong Ju ^a   Choi, Won Mook ^a   Cho, Young Youn ^a   Lee, Yun Bin ^a   Yu, Su Jong ^a   Yoon, Jung Hwan ^a   Lee, Hyo Suk ^a   Kim, Yoon Jun ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; LAMIVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; GENOTYPE; HEPATITIS B; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84896877378     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02483-13     Document Type: Article

References (33)

1. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ. 2009. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleosidenaive patients is rare through 5 years of therapy. Hepatology 49:1503-1514. http://dx.doi.org/10. 1002/hep.22841.
2. Lok AS, McMahon BJ. 2007. Chronic hepatitis B. Hepatology 45:507-539. http://dx.doi.org/10.1002/hep.21513. (Pubitemid 46374607)
3. European Association For The Study Of The Liver. 2009. EASL clinical practice guidelines: management of chronic hepatitis B. J. Hepatol. 50: 227-242. http://dx.doi.org/10.1016/j.jhep.2008.10.001.
4. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. 2008. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol. Int. 2:263-283. http://dx.doi.org/10.1007/s12072-008-9080-3.
5. Chang TT, Lai CL, Chien RN, Guan R, Lim SG, Lee CM, Ng KY, Nicholls GJ, Dent JC, Leung NW. 2004. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 19:1276-1282. http://dx.doi.org/10.1111/j.1440-1746.2004.03428.x. (Pubitemid 39481762)
6. Locarnini S. 2005. Molecular virology and the development of resistant mutants: implications for therapy. Semin. Liver Dis. 25(Suppl 1):9-19. http://dx.doi.org/10.1055/s-2005-915645. (Pubitemid 41254589)
7. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. 2003. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125:1714-1722. http://dx.doi.org/10.1053/j.gastro.2003.09.033. (Pubitemid 37500436)
8. Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, Woessner M, Gardner S, Schiff E. 2003. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 37: 748-755. http://dx.doi.org/10.1053/jhep.2003.50117. (Pubitemid 36397384)
9. Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. 2003. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 38:1267-1273. http://dx.doi.org/10.1053/jhep.2003.50458.
10. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. 2000. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 32:803-806. http://dx.doi.org/10.1053/jhep. 2000.16665.
11. Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, Rizzetto M, Craxi A. 2004. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 40:883-891. http://dx.doi.org/10.1002/hep.1840400418. (Pubitemid 39288121)
12. Lok AS, McMahon BJ. 2009. Chronic hepatitis B: update 2009. Hepatology 50:661-662. http://dx.doi.org/10.1002/hep.23190.
13. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C. 2007. Antiviral drugresistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 46:254-265. http://dx.doi.org/10.1002/hep.21698. (Pubitemid 47171942)
14. Papatheodoridis GV, Manolakopoulos S. 2009. EASL clinical practice guidelines on the management of chronic hepatitis B: the need for liver biopsy. J. Hepatol. 51:226-227. http://dx.doi.org/10.1016/j.jhep.2009.02.017.
15. Chevaliez S, Bouvier-Alias M, Laperche S, Hezode C, Pawlotsky JM. 2010. Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. J. Clin. Microbiol. 48:3641-3647. http://dx.doi.org/10.1128/JCM.01306-10.
16. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H. 2008. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin. Gastroenterol. Hepatol. 6:1315-1341; quiz 1286. http://dx.doi.org/10.1016/j.cgh.2008.08.021.
17. Kao JH. 2002. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J. Gastroenterol. Hepatol. 17:643-650. http://dx.doi.org/10.1046/j.1440-1746.2002.02737.x.
18. Kim HJ, Yoo BC. 2002. The prevalence and clinical significance of precore and core promoter mutations in Korean patients with chronic hepatitis B virus infection. Taehan Kan Hakhoe Chi 8:149-156. (In Korean.)
19. Reijnders JG, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, van Bommel F, Hansen BE, Wedemeyer H, Janssen HL. 2010. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J. Hepatol. 52:493-500. http://dx.doi.org/10.1016/j.jhep.2010.01.012.
20. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D. 2006. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 354:1001-1010. http://dx.doi.org/10.1056/ NEJMoa051285. (Pubitemid 43357804)
21. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L. 2006. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 354:1011-1020. http://dx.doi.org/10.1056/NEJMoa051287. (Pubitemid 43357805)
22. Shouval D, Lai CL, Chang TT, Cheinquer H, Martin P, Carosi G, Han S, Kaymakoglu S, Tamez R, Yang J, Tenney D, Brett-Smith H. 2009. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J. Hepatol. 50:289-295. http://dx.doi.org/10.1016/j.jhep.2008.10.017.
23. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ. 2006. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44:1656-1665. http://dx.doi.org/10.1002/hep.21422. (Pubitemid 44953670)
24. Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, Fang J, Yu CF, Zhang S, Mazzucco CE, Eggers B, Hsu M, Plym MJ, Poundstone P, Yang J, Colonno RJ. 2007. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob. Agents Chemother. 51:902-911. http://dx.doi.org/10.1128/AAC.00833-06. (Pubitemid 46355274)
25. Lim SG, Cheng Y, Guindon S, Seet BL, Lee LY, Hu P, Wasser S, Peter FJ, Tan T, Goode M, Rodrigo AG. 2007. Viral quasi-species evolution during hepatitis Be antigen seroconversion. Gastroenterology 133:951-958. http://dx.doi.org/10. 1053/j.gastro.2007.06.011. (Pubitemid 47381357)
26. Kao JH. 2008. Diagnosis of hepatitis B virus infection through serological and virological markers. Expert Rev. Gastroenterol. Hepatol. 2:553-562. http://dx.doi.org/10.1586/17474124.2.4.553.
27. Liu F, Xiao T, Wang L, Xie JP, Li GH, Liang QL, Luo CH. 2011. Comparison study of HBV-P mutation detection by MALDI-TOF Ms and direct PCR sequencing. Zhonghua Gan Zang Bing Za Zhi 19:436-439. (In Chinese.)
28. Mallory MA, Page SR, Hillyard DR. 2011. Development and validation of a hepatitis B virus DNA sequencing assay for assessment of antiviral resistance, viral genotype and surface antigen mutation status. J. Virol. Methods 177:31-37. http://dx.doi.org/10.1016/j.jviromet.2011.06.009.
29. Vincenti D, Solmone M, Garbuglia AR, Iacomi F, Capobianchi MR. 2009. A sensitive direct sequencing assay based on nested PCR for the detection of HBV polymerase and surface glycoprotein mutations. J. Virol. Methods 159:53-57. http://dx.doi.org/10.1016/j.jviromet.2009.02.027.
30. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. 2006. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44:703-712. http://dx.doi.org/10.1002/hep.21290. (Pubitemid 44433727)
31. Liu Y, Wang C, Zhong Y, Chen L, Li X, Ji D, Wang H, Xin S, Zoulim F, Xu D. 2010. Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B. Antivir. Ther. 15:1185-1190. http://dx.doi.org/10.3851/IMP1679.
32. Ijaz S, Arnold C, Dervisevic S, Mechurova J, Tatman N, Tedder RS, Naoumov NV. 2008. Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy. J. Med. Virol. 80:1160-1170. http://dx.doi.org/10.1002/jmv.21206. (Pubitemid 351705994)
33. Matsuura K, Tanaka Y, Kusakabe A, Hige S, Inoue J, Komatsu M, Kuramitsu T, Hirano K, Ohno T, Hasegawa I, Kobashi H, Hino K, Hiasa Y, Nomura H, Sugauchi F, Nojiri S, Joh T, Mizokami M. 2011. Recommendation of lamivudine-to-entecavir switching treatment in chronic hepatitis B responders: randomized controlled trial. Hepatol. Res. 41:505-511. http://dx.doi.org/10.1111/j.1872-034X.2011. 00807.x.